Fundamentals of Liver Disease - Alcohol-associated Liver Disease

DESCRIPTION
The overall goal is to improve patient care by increasing learner competence and confidence in assessment and management of patients with alcohol-associated liver disease. The current content is geared towards increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved because of the improvements in more providers understanding these key components in the management and care of patients with alcohol-associated liver disease. 

Improving patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with alcohol-associated liver disease.

KEY TOPIC AREAS
Epidemiology and Disease Burden [12 minutes]
Clinical Presentation of Alcohol-associated Liver Disease [15 minutes]
Systemic Concomitant Manifestations [17 minutes]
Diagnosis of Alcohol-associated Liver Disease [20 minutes]
Diagnosis and Management of Alcohol Use Disorder [24 minutes]
Current Medical Treatment Options [24 minutes]
Liver Transplantation [25 minutes]
Integrated Care Model to Treat Dual Pathology [23 minutes]
Pathogenesis and Emerging Therapies [20 minutes]
Prevention and Public Health Measure [16 minutes]

Release date: February 21, 2022
Expiration date: February 20, 2025
Time to complete each module: 30 minutes

CREDITS OFFERED
Continuing Medical Education (CME): For a maximum of 5.00 AMA PRA Category 1 Credits™  
Continuing Education (CE): For a maximum of 5.00 Contact Hour 
You may only earn one Continuing Education Credit type - either CME or CE

Maintenance of Certification (MOC): For a maximum of 5.00 MOC Points

COMPONENTS Online presentations comprised of:
-10 online interactive, narrated modules 10 to 25 minutes in length
-Pre- and post-test questions for each module [5-10 minutes per module]
-Evaluation for CME or CE credit offering [5-10 minutes]

DIRECTIONS
Click "Register" to activate the enduring material. Review all section tabs before you begin. Select module of interest. Complete all components to claim either CME or CE. MOC is available for learners who complete and earn CME.

COPYRIGHT 
All faculty in this activity have given their permission for publication ©2022 AASLD. 

CONTACT INFORMATION 
For questions on CME and MOC content or LiverLearning®, contact online_education@aasld.org 
For questions on CE credit for this enduring material, contact Certificate@AmedcoEmail.com

After the completion of this course, the learner will be able to:

• Identify alcohol associated liver disease
• Apply diagnostic tests appropriately to characterize the disease severity
• Discuss important counseling for long term success
• Recognize treatment/referral priorities
• Identify first line therapies, ongoing clinical trials and follow up to improve long term outcomes

This curriculum was developed for Primary Care Providers and any other healthcare provider interested in liver disease.

Hepatologists
Gastroenterologists
Nurses
Nurse Practitioners
Pharmacists
Physician Assistants
Transplant Coordinators
Surgeons
Fellows/Trainees
Primary Care Physicians
Other healthcare providers

CREDITS OFFERED 
Continuing Medical Education (CME): For a maximum of 5.00 AMA PRA Category 1 Credits™ 
Maintenance of Certification (MOC): For a maximum of 5.00 MOC Points
Continuing Education (CE): For a maximum of 5.00 Contact Hours

ACCREDITATION AND DESIGNATION STATEMENTS  
Continuing Medical Education (CME)  The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this enduring activity for a maximum of 5.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC) 
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Education (Nursing Contact Hours)  
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Association for the Study of Liver Diseases.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement – Amedco LLC designates this enduring material activity for a maximum of 5.00 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

CLAIMING CME CREDITS 
Physicians and other health care professionals for a maximum of 5.00 AMA PRA Category 1 Credits™ for this enduring continuing medical education material must completed by February 20, 2025. 

CLAIMING CE CREDITS
Nurses for a maximum of 5.00 contact hours for this enduring continuing education material must be completed by February 20, 2025. 

CLAIMING ABIM MOC POINTS  
Physicians seeking ABIM MOC credit must complete the enduring material by February 20, 2025. Requests for MOC after this date will not be honored. MOC Points will be reported to the ABIM by the end of each month through March 2025 for individuals who successfully complete MOC.

HOW TO EARN AND CLAIM MOC POINTS For each module that you wish to claim MOC points for you must:

             o    Complete the pre-tests

             o    Watch video presentations

             o    Complete the post-tests and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing  score.)

             o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

MOC completions are collected on the 15th of each month and submitted to the ABIM by the last day of the month. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.

MOC points are available for ABIM board certified physicians only.

DISCLOSURE OF CONFLICTS OF INTEREST

AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing health-care related products and/or services. Disclosures are collected prior to the start of the educational activity any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning. The faculty, organizers and reviewers have reported the following disclosures:

Juan P. Arab, MD
Faculty
Nothing to Disclose

Suthat Liangpunsakul, MD, MPH, AGAF, FAASLD
Faculty
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Durect Corporation, TwoXar, Surrozen

Gene Y. Im, MD
Faculty
Nothing to disclose

Michael R. Lucey, MD, FAASLD
Faculty
Research Grants: Abbvie; NIAAA; PharmaSolutions; Intercept Pharma; Exact Sciences
Scientific Consultant/Advisory to Industry or Commercial Enterprise, including Development of Educational Presentations: Novartis 

Lorenzo Leggio, MD, PhD
Faculty
Intellectual Property Rights (Patents, Royalties, Licensing fees): Royalties for textbook edited by Routledge

Craig J. McClain, MD, FAASLD
Faculty
Research Grants: NIH, VA, GenFit, Target NASH, Diapharma, Gilead, Intercept, Novartis
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: US Federal Trade Commission

Ashwani K. Singal, MD, MS, FACG, FAASLD
Faculty
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: CLD Foundation, Medscape Gastroenterology, Up-To-Date.
Research Grants: American College of Gastroenterology, National Institute of Alcohol Abuse and Alcoholism, National Institute of Digestive Diseases Diabetes and Kidney Diseases, GiLead

Gerald (Scott) Winder, MD
Faculty
Nothing to disclose

Gyongyi Szabo, MD, PhD, FAASLD
Faculty
Research Grants: NIH-NIAAA, Gilead
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: AASLD, Alinylam Pharma, Intercept, Novartis, Allergan, Glympse Bio, Generon

Lauren D. Nephew, MD, MSCE
Faculty
Nothing to disclose

Amanda J. Chaney, DNP, APRN, FNP-BC
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Royalties: Springer Publishing-Author 

Rena Fox, MD 
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Grant/Research Support: Gilead Sciences

Sonal Kumar, MD 
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Scientific Consultant/Advisory to Industry or Commercial Enterprise, including Development of educational Presentations: Gilead Sciences, Intercept and AbbVie 
Speaker's Bureau: Gilead Sciences and AbbVie
Grant/Research Support: Gilead Sciences, AbbVie and Intercept

Adam Mikolajczyk, MD 
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Nothing to disclose

April G. Morris, FNP
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Speaker's Bureau: Gilead, AbbVie, Intercept Pharmaceuticals
Scientific Consultant/Advisory to Industry or Commercial Enterprise, including Development of educational Presentations: AbbVie

Paul Pockros, MD
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Nothing to disclose

Amol Rangnekar, MD 
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Nothing to disclose

Raj Vuppalanchi, MD, FAASLD 
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Data Safety Monitoring Board for Industry or Commercial Enterprise: Enanta, Enyio and LabCorp/Covance
Served as PI for multicenter clinical trials: Intercept, Gilead, Zydus Discovery, Novo Nordisk and Eli Lilly

Susan Zapatka, DNP 
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Nothing to disclose

Dominique Clayton 
AASLD Staff
Nothing to disclose

Sheryl Morgan
Amedco LLC Staff
Nothing to disclose

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Acknowledgement of Commercial Support: No commercial support was received for this enduring material activity.